Vast majority of surveyed European physicians see need for ultra-fast insulins

The vast majority of surveyed physicians in the EU5 countries (France, Germany, Italy, Spain and the UK) identify an unmet need for ultra-fast insulins for the treatment of type 1 diabetes, according to the findings of advisory firm Decision Resources.

The new European Physician & Payer Forum report titled Type 1 Diabetes in Europe: How Will Clinicians and Payers React to Future Therapeutic Approaches, Novel Insulin Formulations, and Biosimilar Competition? finds that surveyed EU5 clinicians see a role for ultra-fast insulin for patients currently treated with injection as well as for patients treated with continuously infused insulin administered via an insulin pump.

“On average, surveyed clinicians in the EU5 expect to prescribe a novel ultra-fast insulin to 24% to 48% of their patients who are currently injecting insulin,” said Decision Resources’ analyst Matthew Scutcher, adding that “European clinicians also expect to prescribe this agent to 21% to 26% of their patients who are treated with a pump.”